IVIG

Org: Departments of Medicine and Oncology, McGill University, Centre de recherche du CHUM, Institut du Cancer de Montréal, Meakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Division of Cardiology, McGill University,

Clinical trial

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Status: Recruiting, Estimated PCD: 2022-12-01

Clinical trial

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease: A Multicentre Randomised Controlled Trial

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

Role of Immunoglobulin in Male Infertility

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Status: Not yet recruiting, Estimated PCD: 2026-06-22

Clinical trial

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS)

Status: Completed, Estimated PCD: 2023-06-26

Clinical trial

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome：a Prospective, Multicenter, Non-randomized Controlled Intervention Study

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Status: Active (not recruiting), Estimated PCD: 2025-03-31

Clinical trial

Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS

Status: Withdrawn, Estimated PCD: 2013-12-01

Clinical trial

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

Status: Not yet recruiting, Estimated PCD: 2024-04-01

Abstract

Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.

Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Management of immune related adverse events through electronic multidisciplinary consultation: Five years of experience from Peking Union Medical College Hospital.

Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

An evaluation of cisplatin, doxorubicin, and cyclophosphamide (PAC) compared to other regimens for patients with unresectable or metastatic thymic carcinoma: A single-institution retrospective analysis.

Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,

Abstract

Comorbidities in patients with sarcoma: Insights from the National In-Patient Database from 2006 to 2014.

Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,